Related Experiment Video
Updated: Aug 11, 2026
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
Effect of a novel antineoplastic drug olipifat on antitumor immunity in mice
V M Bukhman1, D A Bodyagin, E R Pereverzeva
1G. F. Gauze Institute for New Antibiotics, Russian Academy of Medical Sciences, Moscow.
Abstract:
Olipifat is an antineoplastic drug containing pyrophosphate and a product of special lignin processing. Donor C57Bl/6J mice with syngeneic B16 melanoma received a single 5-day course of olipifat. Effect of olipifat on antitumor resistance was evaluated by local neutralization test [3]. In animals with rapid melanoma growth, splenic cells from intact donors stimulated tumor growth. Olipifat abolished this growth-stimulating effect of splenocytes. In animals with slow melanoma growth, splenocytes had no effect on the growth of melanoma or Lewis lung cancer. In this case, splenocytes from olipifat-treated donors completely arrested the growth of melanoma B16 and decelerated the growth of Lewis lung carcinoma.
Insights
Olipifat, an antineoplastic drug, demonstrated significant potential in enhancing antitumor resistance. Treatment with olipifat modulated splenocyte activity, inhibiting tumor growth in melanoma models.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Olipifat is an antineoplastic drug derived from pyrophosphate and processed lignin.
- Antitumor resistance is a critical factor in cancer treatment outcomes.
- The immunomodulatory effects of novel drugs require thorough investigation.
Purpose of the Study:
- To evaluate the effect of olipifat on antitumor resistance.
- To investigate the impact of olipifat on splenocyte function in cancer models.
Main Methods:
- Olipifat was administered to C57Bl/6J mice bearing syngeneic B16 melanoma.
- Antitumor resistance was assessed using a local neutralization test.
- Splenocyte activity was analyzed in relation to tumor growth.
Main Results:
- In mice with rapid melanoma growth, olipifat abolished the tumor-growth-stimulating effect of splenocytes from intact donors.
- In mice with slow melanoma growth, splenocytes from olipifat-treated donors arrested B16 melanoma growth and decelerated Lewis lung carcinoma growth.
- Olipifat modulated splenocyte function, shifting it from tumor-growth-promoting to tumor-inhibiting.
Conclusions:
- Olipifat exhibits immunomodulatory properties that enhance antitumor resistance.
- The drug shows promise in reversing the immunosuppressive effects of splenocytes in certain cancer contexts.
- Further research into olipifat's mechanisms and therapeutic potential is warranted.
